TLR7 and neoplasm: Small interfering RNA (siRNA) can be modified to inhibit the expression of certain genes when given as vaccines, it has a remarkable effect on the treatment of melanoma in mice.[110] A DC‐targeted nanovaccine has been proposed; it includes the phospholipid bilayer from tumor cell membrane and imiquimote (IMQ), a clinically approved TLR‐7 agonist.